Slow Start to VC Investments in 2013, Spec Pharma Swells
BioWorld Today Columnist
Did all the venture capitalists get washed out to sea by Superstorm Sandy? Maybe they all followed in Benedict's footsteps and resigned? Because they sure weren't doing very many deals in the first quarter.
According to BioWorld data for VC funding of U.S. companies developing therapeutics, the number of deals dropped from 25 in the first quarter of last year to 21 this year.
The total value of those deals looked even bleaker, falling 27 percent from $391 billion last year to just $285.5 billion this year.
Suite: 1100 | Atlanta, Georgia 30346, USA
Outside of the US
In the U.S. and Canada: +1-800-336-4474
Outside the U.S.: +44-203-684-1796
Hours: Monday - Friday, 8:00am - 6:00 pm EST
Sign up for Highlights FREE e-mail newsletter